Subsidiary SHR-2906 injection of Jiangsu Hengrui Pharmaceuticals (600276.SH) approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) has announced that its subsidiary, Beijing Shengdi Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection. The clinical trial is expected to begin soon. SHR-2906 injection is a biopharmaceutical developed by the company, which is expected to have a synergistic effect on regulating sugar and fat metabolism, controlling weight by reducing energy intake, promoting energy expenditure, and improving the metabolic environment in the body. It is believed to have clinical efficacy in treating overweight and obesity. Currently, there are no similar drugs approved for market domestically or internationally. As of now, the total research and development investment in the SHR-2906 injection project is approximately 17.06 million yuan.